NCT04679584 COVIDOM: Longterm Morbidity of SARS-CoV-2 Infection and COVID-19 Disease - Consequences for Health Status and Quality of Life
| NCT ID | NCT04679584 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital Schleswig-Holstein |
| Condition | COVID-19 |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2020-11-16 |
| Primary Completion | 2021-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,000 participants in total. It began in 2020-11-16 with a primary completion date of 2021-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
COVID-19 is a novel disease caused by SARS-CoV-2 that primarily affects the lungs but also various other organs of the body already in early stages of the disease. Due to the multiple organ involvements in the acute phase, it is conceivable that - in a significant proportion of patients - longterm sequels in various organ systems might occur, thereby impacting the individual's health status and quality of life; and posing a relevant burden to the resources of the health care system Assessment of SARS-CoV-2-longterm morbidity and sequels on the population level: In order to identify and treat these sequels in a timely fashion and to get a sense of the prevalence of such SARS-CoV-2 sequels on the population level, it is important to collect follow-up data and to comprehensively re-examine a population-representative sample of SARS-CoV-2 infected individuals. Within the COVIDOM study we will conduct deep clinical and biochemical phenotyping in population-representative samples in Germany. This will allow novel insights into disease pathogenesis and chronicity of virus infections.
Eligibility Criteria
Inclusion Criteria: * PCR-confirmed SARS-CoV-2 infection * living in one of the target areas * age at least 18 years * written informed consent Exclusion Criteria: * Acute SARS-CoV-2 infection or reinfection
Contact & Investigator
Stefan Schreiber, Prof. Dr.
STUDY DIRECTOR
Internal Medicine Department I, UKSH Kiel
Frequently Asked Questions
Who can join the NCT04679584 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying COVID-19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04679584 currently recruiting?
Yes, NCT04679584 is actively recruiting participants. Contact the research team at s.schreiber@mucosa.de for enrollment information.
Where is the NCT04679584 trial being conducted?
This trial is being conducted at Würzburg, Germany, Kiel, Germany, Berlin, Germany.
Who is sponsoring the NCT04679584 clinical trial?
NCT04679584 is sponsored by University Hospital Schleswig-Holstein. The principal investigator is Stefan Schreiber, Prof. Dr. at Internal Medicine Department I, UKSH Kiel. The trial plans to enroll 2,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.